RASSF1A-Hippo pathway link in patients with urothelial carcinoma of bladder: plausible therapeutic target.
CTGF
CYR61
Chemosensitivity
Hippo pathway
RASSF1A
Urinary bladder cancer
Journal
Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
20
05
2019
accepted:
03
11
2019
pubmed:
23
11
2019
medline:
19
3
2020
entrez:
23
11
2019
Statut:
ppublish
Résumé
RASSF1A is a tumor suppressor gene, and its hypermethylation has been observed in cancers. RASSF1A acts as an upstream regulator of Hippo pathway and modulates its function. The aim of this study was to analyze expression of RASSF1A, Hippo pathway molecules (YAP, MST) and downstream targets (CTGF, Cyr61 and AREG) in bladder cancer patients. Later, the link between RASSF1A and Hippo pathway and a potential therapeutic scope of this link in UBC were also studied. MSPCR was performed to study methylation of RASSF1A promoter. Expression of molecules was studied using qPCR, Western blot and IHC. The link between RASSF1A and Hippo pathway was studied using Spearman's correlation in patients and validated by overexpressing RASSF1A in HT1376 cells and its effect on Hippo pathway was observed using qPCR and Western blot. Further therapeutic potential of this link was studied using MTT and PI assays. The expression of RASSF1A was lower, whereas the expression of YAP, CTGF and CYR61 was higher. The expression of RASSF1A protein gradually decreased, while the expression of YAP, CTGF and CYR61 increased with severity of disease. Based on Spearman's correlation, RASSF1A showed a negative correlation with YAP, CTGF and CYR61. YAP showed a positive correlation with CTGF and CYR61. To validate this link, RASSF1A was overexpressed in HT1376 cells. Overexpressed RASSF1A activated Hippo pathway, followed by a decrease in CTGF and CYR61 at mRNA, and enhanced cytotoxicity to chemotherapeutic drugs. This study finds a previously unrecognized role of RASSF1A in the regulation of CTGF and CYR61 through mediation of Hippo pathway in UBC and supports the significance of this link as a potential therapeutic target for UBC.
Identifiants
pubmed: 31754973
doi: 10.1007/s11010-019-03648-y
pii: 10.1007/s11010-019-03648-y
doi:
Substances chimiques
CCN1 protein, human
0
CCN2 protein, human
0
Cysteine-Rich Protein 61
0
RASSF1 protein, human
0
Tumor Suppressor Proteins
0
Connective Tissue Growth Factor
139568-91-5
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-63Références
Biochemistry (Mosc). 2005 May;70(5):576-83
pubmed: 15948711
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2270-5
pubmed: 21262812
Cancer Cell. 2009 Nov 6;16(5):425-38
pubmed: 19878874
Am J Pathol. 2014 Apr;184(4):937-943
pubmed: 24485923
Cancer Res. 2011 Apr 1;71(7):2728-38
pubmed: 21349946
Cancer Res. 2008 Apr 1;68(7):2266-74
pubmed: 18381433
J Carcinog. 2012;11:3
pubmed: 22438769
Cell. 2006 Jun 30;125(7):1253-67
pubmed: 16814713
Mol Cell Biochem. 2018 Sep;446(1-2):105-114
pubmed: 29368096
Mol Cancer Res. 2013 Jul;11(7):748-58
pubmed: 23594797
Int J Cancer. 2003 May 1;104(5):611-6
pubmed: 12594816
Mod Pathol. 2007 Mar;20(3):331-8
pubmed: 17277767
Dis Markers. 2007;23(1-2):73-87
pubmed: 17325427
Cancer Res. 2001 Dec 15;61(24):8917-23
pubmed: 11751417
Oncogene. 2002 Nov 21;21(53):8178-85
pubmed: 12444554
Curr Biol. 2007 Apr 17;17(8):700-5
pubmed: 17379520
J Biol Chem. 2014 Nov 7;289(45):31287-95
pubmed: 25225292
J Clin Endocrinol Metab. 2001 Apr;86(4):1707-15
pubmed: 11297607
Tumori. 2007 Jan-Feb;93(1):4-12
pubmed: 17455864
Clin Cancer Res. 2014 Feb 15;20(4):837-46
pubmed: 24323901
Cancer. 2009 Oct 1;115(19):4576-85
pubmed: 19551889
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10
pubmed: 16894141
Int J Mol Med. 2015 Dec;36(6):1451-63
pubmed: 26498181
Biochim Biophys Acta. 2009 Dec;1796(2):114-28
pubmed: 19344752
J Urol. 2010 Apr;183(4):1604-10
pubmed: 20172544
Histol Histopathol. 2003 Apr;18(2):665-77
pubmed: 12647816
Oncol Lett. 2016 Oct;12(4):2277-2282
pubmed: 27698789
Head Neck. 2010 Dec;32(12):1665-73
pubmed: 20848406
Oncogene. 2016 Mar 24;35(12):1541-53
pubmed: 26119935
Oncol Rep. 2013 Feb;29(2):840-6
pubmed: 23232767
Urol Oncol. 2012 Mar-Apr;30(2):177-81
pubmed: 20800513
Hum Pathol. 2008 Nov;39(11):1582-9
pubmed: 18703216
Histol Histopathol. 2005 Apr;20(2):645-63
pubmed: 15736067
Nat Cell Biol. 2009 Dec;11(12):1444-50
pubmed: 19935651
Nat Genet. 2000 Jul;25(3):315-9
pubmed: 10888881
PLoS One. 2007 Jun 20;2(6):e534
pubmed: 17579708
Springerplus. 2014 Apr 05;3:178
pubmed: 24790823
BMC Cancer. 2013 Jul 19;13:349
pubmed: 23870412
Cancer Res. 2006 Mar 1;66(5):2562-9
pubmed: 16510573
BMC Cancer. 2009 Aug 22;9:291
pubmed: 19698122
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2004 Mar 15;10(6):1887-93
pubmed: 15041703